Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipafricept (OMP-54F28) + Sorafenib in HCC
NCT02069145Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- May 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipafricept in hepatocellular carcinoma (HCC), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Safety and tolerability of OMP-54F28 in combination with sorafenib. Started Jan 2014; status: completed.
02
Drugs
ipafricept
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02069145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069145.